RT Journal Article
SR Electronic
T1 A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20107144
DO 10.1101/2020.05.19.20107144
A1 Lorenzo-Redondo, Ramon
A1 Nam, Hannah H.
A1 Roberts, Scott C.
A1 Simons, Lacy M.
A1 Jennings, Lawrence J.
A1 Qi, Chao
A1 Achenbach, Chad J.
A1 Hauser, Alan R.
A1 Ison, Michael G.
A1 Hultquist, Judd F.
A1 Ozer, Egon A.
YR 2020
UL http://medrxiv.org/content/early/2020/06/21/2020.05.19.20107144.abstract
AB Background The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID- 19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. Here, we aimed to investigate the phylogenetic characteristics of SARS-CoV-2 infections in Chicago, Illinois and assess their relationship to clinical parameters.Methods We performed whole-genome sequencing of SARS-CoV-2 isolates collected from COVID-19 patients in a Chicago healthcare system in mid-March, 2020. Using these and other publicly available sequences, we performed phylogenetic, phylogeographic, and phylodynamic analyses. Patient data was assessed for correlations between demographic or clinical characteristics and virologic features.Findings The 88 SARS-CoV-2 genome sequences in our study separated into three distinct phylogenetic clades. Clade 1 was most closely related to viral sequences from New York, and showed evidence of rapid expansion across the US, while Clade 3 was most closely related to those in Washington state. Clade 2 was localized primarily to the Chicago area with limited evidence of expansion elsewhere. At the time of diagnosis, patients infected with Clade 1 viruses had significantly higher average viral loads in their upper airways relative to patients infected with Clade 2 viruses, independent of time to symptom onset and disease severity.Interpretation These results show that multiple variants of SARS-CoV-2 are circulating in the Chicago area that differ in their relative viral loads in patient upper airways. These data suggest that differences in virus genotype impact viral load and may in turn influence viral transmission and spread.Funding Dixon Family Translational Research Award, Northwestern University Clinical and Translational Sciences Institute (NUCATS), National Institute of Allergy and Infectious Diseases (NIAID)Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by: a Dixon Translational Research Grant made possible by the generous support of the Dixon family (E.A.O. and J.F.H.); a COVID-19 Supplemental Research award from the Northwestern Center for Advanced Technologies (NUCATS - M.G.I., C.J.A., and J.F.H.), the Gilead Sciences Research Scholars Program in HIV (J.F.H.), and NIH grants K22 AI136691 (J.F.H.), U19 AI135964 (E.A.O., A.R.H.), K24 AI04831 (A.R.H.), and T32 AI095207 (H.H.N., S.C.R.). The funding sources had no role in the design of the study, in the collection/analysis/ interpretation of the data, in the writing of the report, or in the decision to publish. The corresponding authors had access to all of the data in the study and had final responsibility for the decision to submit this work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Institutional Review Board of Northwestern University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequence data that support the findings of this study have been deposited in GISAID (https://www.gisaid.org/) with the accession codes given in Supplemental Table 1